Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Swedish Research Council | OTHER_GOV |
| Swedish Heart Lung Foundation | OTHER |
| Riksförbundet HjärtLung | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
High-intensity exercise is essential for optimal development of cardiorespiratory fitness and health. This is, however, challenging for most people with chronic obstructive pulmonary disease (COPD) due to ventilatory limitations, leading to exercise at lower intensities accompanied by suboptimal stress on the cardiovascular and muscular system.
The aims of this cross-over trial is:
In this study, eligible participants attended the facility four times within 14 days with at least 48 hours of rest between visits.
Exercise tests (visit 1, week 1):
After pulmonary functions tests, a CPET on a stationary bicycle was performed according to international guidelines. After 1.5 hours of recovery, a BCST was performed to assess anaerobic exercise capacity and determine exercise intensities for supramaximal HIIT.
Exercise sessions (visit 2 - week 1; visit 3 - week 2; visit 4 - week 2):
The order of the two first exercise sessions (HIIT at 60% of MPO6 or MICT) on a stationary bicycle were randomized. The exercise session at HIIT at 80% of MPO6 was always the third exercise session.
During all exercise sessions, blood collection was performed at baseline after a 15-minute seated rest. During HIIT, blood was collected immediately after, and 30 minutes after the 10-minute HIIT period. For MICT, blood was collected after 10 minutes (isotime in relation to HIIT), immediately after, and 30 minutes of cycling at 60% MAP.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chronic Obstructive Pulmonary Disease (COPD) | Experimental | People with chronic obstructive pulmonary disease (COPD) (n = 16) |
|
| Healthy Controls (HC) | Active Comparator | Healthy controls matched on age, sex and objectively measured physical activity (n = 16) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Supramaximal High-Intensity Interval Training at 60% of MPO6 | Other | Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST. Duration supramaximal HIIT: 10 minutes Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle. |
| Measure | Description | Time Frame |
|---|---|---|
| Exercise intensity | Produced watt at the set training intensity | During visit 2 (week 1) |
| Exercise intensity | Produced watt at the set training intensity | During visit 3 (week 2) |
| Exercise intensity | Produced watt at the set training intensity | During visit 4 (week 2) |
| Brain-derived neurotrophic factor (BDNF) | Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. | During visit 2 (week 1) |
| Brain-derived neurotrophic factor (BDNF) | Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. | During visit 3 (week 2) |
| Brain-derived neurotrophic factor (BDNF) | Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. | During visit 4 (week 2) |
| Measure | Description | Time Frame |
|---|---|---|
| Cardiorespiratory demand | Gas exchange parameters (e.g. VO2, VCO2, ventilatory equivalents, RER) and lung volumes (e.g. VE, Vt, breathing frequency) obtained with a metabolic cart (breath by breath methodology) and heart rate (beats per minutes) during exercise during exercise. | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
Not provided
COPD
Inclusion Criteria:
Exclusion Criteria:
HC
Inclusion Criteria:
- Age: > 40 years
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andre Nyberg, PhD | Umeå University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Umeå University | Umeå | Sweden |
Undecided: It is not yet known if individual participant data (IPD) will be available to other researchers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Moderate-Intensity Continuous Training | Other | MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle. Duration MICT: 20 minutes Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle. |
|
|
| Supramaximal High-Intensity Interval Training at 80% of MPO6 | Other | Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST. Duration supramaximal HIIT: 10 minutes Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle. |
|
|
| Venous blood lactate concentration | Measured before, during and after exercise. | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Rating of perceived exertion | Rating of perceived exertion scale (Borg RPE). Minimum value = 6 Maximum value = 20 A higher score means higher exertion. | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Rating of symptoms | Rating of dyspnea and leg fatigue symptoms via Borg CR (category ratio) 10 during exercise Minimum value = 0 Maximum value = 10 A higher score means higher severity of symptoms | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Peripheral blood oxygen saturation (SpO2) | SpO2 during exercise | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Blood pressure | Systolic and diastolic blood pressure during exercise | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Circulating levels of neurotrophic factors | Plasma or serum concentration (measured as mg/l, ng/l, or pq/l) of irisin, cathepsin B, clusterin, in obtained venous blood samples before, during and after exercise. | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Circulating levels of exerkines | Plasma or serum concentration of interleukin (IL)-1b, IL-4, IL-6, IL-8, IL-10, IL-13, IL-15, IL-17, tumor necrosis factor (TNF)-α, vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and adiponectin in obtained venous blood samples before, during and after exercise. | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Exercise session completion | Number of uninterrupted exercise sessions | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Exercise preference | Preference for HIIT at 60% of MPO6 or MICT, defined as answer on the following question: "If the MICT and HIIT would be equally effective in improving your health and physical capacity, which one would you prefer to perform?" | At the end of visit 3 (week 2) |
| Session RPE | Rating of session RPE on Borg CR (category ratio) 10 is assessed 30 min after every exercise session Minimum value = 0 Maximum value = 10 A higher score means higher session exertion | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| Exercise capacity | Maximal aerobic power (MAP) expressed as produced watt at VO2peak | During visit 1 (CPET; week 1) |
| Exercise intensity | Maximum mean power output for 30 seconds (MPO30) in watts | During visit 1 (BCST; week 1) |
| Adverse events | Occurence and severity of adverse events. The severity of adverse events will be assessed and rated into four different categories: 1) minor and temporary, 2) serious symptoms (potential risk of severe injury or life threatening, 3) manifest injury or disease and 4) death. An adverse event rate will be calculated for each participant as the total number of sessions during which any adverse events occurred divided by the total number of attended sessions. | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided